Intercell AG / Iomai Inc

Exclusively advised in the divestiture of the US Vaccine Biotech company Iomai to Intercell AG, Vienna, Austria for a total cash and stock consideration of US$ 189m.

• April 2008: Final LOI, as per the terms of the agreement, 59% shareholders of Iomai will get cash and the remaining 41% will be satisfied through the issue of 1.7m Intercell shares
• May 2008 : After the intervention of an interloper, Intercell raises the offer price to US$ 6.60 per share representing a premium of 147 % over Iomai‘s US$ 2.67 closing share price of as of 9 May 2008, the last trading day prior to the announcement date. June 2008: Completion of the tender-offer period.